Skip to main content

Table 4 Background of patients stratified by administration of remdesivir (with or without remdesivir) after matching

From: Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study

 

Without remdesivir

With remdesivir

p valuea

n

%

n

%

Age

 < 60

90

30.6

30

30.6

1.000

 60 s

51

17.3

17

17.3

 

 ≥ 70

153

52.0

51

52.0

 

Gender

 Male

210

71.7

67

68.4

0.524

 Female

83

28.3

31

31.6

 

Primary disease

 Chronic glomerulonephritis

40

15.1

20

22.5

0.372

 Diabetes mellitus

149

56.2

43

48.3

 

 Nephrosclerosis

39

14.7

12

13.5

 

 Others

37

14.0

14

15.7

 

Duration of dialysis

 < 1 year

37

12.9

14

14.4

0.754

 1 to < 5 years

100

34.8

31

32.0

 

 5 to < 10 years

72

25.1

30

30.9

 

 10 to < 15 years

42

14.6

13

13.4

 

 ≥ 15 years

36

12.5

9

9.3

 

Complication

 Hypertension

  No

156

55.1

42

42.9

0.046

  Yes

127

44.9

56

57.1

 

 Diabetes mellitus

  No

124

43.5

46

46.9

0.558

  Yes

161

56.5

52

53.1

 

 Cardiovascular disease

 No

156

56.5

49

51.6

0.406

  Yes

120

43.5

46

48.4

 

Chronic respiratory disease

  No

249

89.6

83

87.4

0.571

  Yes

29

10.4

12

12.6

 

 Peripheral arterial disease

  No

230

84.9

75

78.9

0.201

  Yes

41

15.1

20

21.1

 

 Malignancy

  No

234

84.2

83

87.4

0.509

  Yes

44

15.8

12

12.6

 

 Number of complication

  0

38

13.1

10

10.2

0.778

  1

84

29.1

29

29.6

 

   ≥ 2

167

57.8

59

60.2

 

Oxygenation

 No

69

23.5

23

23.5

1.000

 Yes

159

54.1

53

54.1

 

 Ventilator or ECMO

66

22.4

22

22.4

 
  1. ECMO extracorporeal membrane oxygenation
  2. aFisher’s exact test